



**HAL**  
open science

# Mechanism of cystathionine- $\beta$ -synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II)

Karim Zuhra, Theodora Panagaki, Elisa Randi, Fiona Augsburger, Marc Blondel, Gaelle Friocourt, Yann Hérault, Csaba Szabo

► **To cite this version:**

Karim Zuhra, Theodora Panagaki, Elisa Randi, Fiona Augsburger, Marc Blondel, et al.. Mechanism of cystathionine- $\beta$ -synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II). *Biochemical Pharmacology*, 2020, 182, pp.114267. 10.1016/j.bcp.2020.114267. hal-03065495

**HAL Id: hal-03065495**

**<https://hal.science/hal-03065495v1>**

Submitted on 26 Nov 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



## Mechanism of cystathionine- $\beta$ -synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II)

Karim Zuhra<sup>a</sup>, Theodora Panagaki<sup>a</sup>, Elisa B. Randi<sup>a</sup>, Fiona Augsburger<sup>a</sup>, Marc Blondel<sup>b</sup>, Gaëlle Friocourt<sup>b</sup>, Yann Herault<sup>c</sup>, Csaba Szabo<sup>a,\*</sup>

<sup>a</sup> Chair of Pharmacology, Department of Science and Medicine, University of Fribourg, Fribourg, Switzerland

<sup>b</sup> Inserm UMR 1078, Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, Etablissement Français du Sang (EFS) Bretagne, CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, Brest, France

<sup>c</sup> Université de Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), 1 Rue Laurent Fries, 67404 Illkirch, France

### ARTICLE INFO

#### Keywords:

H<sub>2</sub>S  
Gasotransmitters  
Disulfiram  
Mitochondria  
Bioenergetics  
Cancer  
Down syndrome

### ABSTRACT

**Background:** Hydrogen sulfide (H<sub>2</sub>S) is an endogenous mammalian gasotransmitter. Cystathionine  $\beta$ -synthase (CBS), cystathionine  $\gamma$ -lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST) are the principal enzymes responsible for its biogenesis. A recent yeast screen suggested that disulfiram (a well-known inhibitor of aldehyde dehydrogenase and a clinically used drug in the treatment of alcoholism) may inhibit CBS in a cell-based environment. However, prior studies have not observed any direct inhibition of CBS by disulfiram. We investigated the potential role of bioconversion of disulfiram to bis(N,N-diethyldithiocarbamate)-copper(II) complex (CuDDC) in the inhibitory effect of disulfiram on H<sub>2</sub>S production and assessed its effect in two human cell types with high CBS expression: HCT116 colon cancer cells and Down syndrome (DS) fibroblasts.

**Methods:** H<sub>2</sub>S production from recombinant human CBS, CSE and 3-MST was measured using the fluorescent H<sub>2</sub>S probe AzMc. Mouse liver homogenate (a rich source of CBS) was also employed to measure H<sub>2</sub>S biosynthesis. The interaction of copper with accessible protein cysteine residues was evaluated using the DTNB method. Cell proliferation and viability were measured using the BrdU and MTT methods. Cellular bioenergetics was evaluated by Extracellular Flux Analysis.

**Results:** While disulfiram did not exert any significant direct inhibitory effect on any of the H<sub>2</sub>S-producing enzymes, its metabolite, CuDDC was a potent inhibitor of CBS and CSE. The mode of its action is likely related to the complexed copper molecule. In cell-based systems, the effects of disulfiram were variable. In colon cancer cells, no significant effect of disulfiram was observed on H<sub>2</sub>S production or proliferation or viability. In contrast, in DS fibroblasts, disulfiram inhibited H<sub>2</sub>S production and improved proliferation and viability. Copper, on its own, failed to have any effects on either cell type, likely due to its low cell penetration. CuDDC inhibited H<sub>2</sub>S production in both cell types studied and exerted the functional effects that would be expected from a CBS inhibitor: inhibition of cell proliferation of cancer cells and a bell-shaped effect (stimulation of proliferation at low concentration and inhibition of these responses at higher concentration) in DS cells. Control experiments using a chemical H<sub>2</sub>S donor showed that, in addition to inhibiting CBS and CSE, part of the biological effects of CuDDC relates to a direct reaction with H<sub>2</sub>S, which occurs through its complexed copper.

**Conclusions:** Disulfiram, via its metabolite CuDDC acts as an inhibitor of CBS and a scavenger of H<sub>2</sub>S, which, in turn, potently suppresses H<sub>2</sub>S levels in various cell types. Inhibition of H<sub>2</sub>S biosynthesis may explain some of the previously reported actions of disulfiram and CuDDC *in vitro* and *in vivo*. Disulfiram or CuDDC may be considered

**Abbreviations:** XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide; 3-MP, 3-mercaptopyruvate; 3-MST, 3-mercaptopyruvate sulfurtransferase; BrdU, 5-bromo-2'-deoxyuridine; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); AzMc, 7-azido-4-methylcoumarin; ALDH, aldehyde dehydrogenase; AOAA, aminooxyacetic acid; AMA, antimycin A; CuDDC, bis(N,N-diethyldithiocarbamate)-copper(II) complex; BSA, bovine serum albumin; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; CBS, cystathionine beta-synthase; CSE, cystathionine gamma-lyase; Cys, cysteine; CcOX, cytochrome c oxidase; DDC, diethyldithiocarbamate; DMSO, dimethyl sulfoxide; DS, Down's syndrome; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; H<sub>2</sub>S, hydrogen sulfide; Oligo, oligomycin; PLP, pyridoxal 5'-phosphate; ROS, reactive oxygen species; Rot, rotenone; SAM, S-(5'-adenosyl)-L-methionine; SQR, sulfide:quinone oxidoreductase; MTT, thiazolyl blue tetrazolium bromide; TS, transsulfuration pathway; TCEP, tris(2-carboxyethyl)phosphine; ZnDDC, zinc diethyldithiocarbamate.

\* Corresponding author.

E-mail address: [csaba.szabo@unifr.ch](mailto:csaba.szabo@unifr.ch) (C. Szabo).

<https://doi.org/10.1016/j.bcp.2020.114267>

Received 27 August 2020; Received in revised form 1 October 2020; Accepted 1 October 2020

Available online 7 October 2020

0006-2952/© 2020 Elsevier Inc. All rights reserved.

as potential agents for the experimental therapy of various pathophysiological conditions associated with H<sub>2</sub>S overproduction.

## 1. Introduction

Hydrogen sulfide (H<sub>2</sub>S) is now viewed as an important endogenous mammalian gasotransmitter, which regulates a variety of physiological and pathophysiological processes in health and disease. The expression of various H<sub>2</sub>S-producing enzymes and, consequently, the levels of H<sub>2</sub>S are increased in various diseases, including local and systemic inflammation, critical illness, several forms of cancer and in Down syndrome [DS] [55,53,58].

Three principal mammalian H<sub>2</sub>S-producing enzymes are known: cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) (reviewed in [18,22,45,53]). Both CBS and CSE lead to H<sub>2</sub>S generation using cysteine as substrate, while 3-MST catalyzes the conversion of 3-mercaptopyruvate (3-MP) to pyruvate and an enzyme-bound persulfide which is then released in the presence of a sulfur acceptor. Physiological modulation of the activity of the three enzymes has been shown to occur via interaction with allosteric effectors and/or changes of the oxidation state of redox sensitive centers [46,17]. In various cancers, and in DS, the increased biological H<sub>2</sub>S levels are the result of the upregulation of CBS as well as 3-MST, with opposite biological outcomes. On the one hand, cancer cells are equipped with a sophisticated sulfide detoxifying enzymatic machinery which, through the inner mitochondrial membrane-associated sulfide: quinone oxidoreductase (SQR), injects H<sub>2</sub>S-derived electrons along the electron transport chain, thus supporting proliferation and bioenergetics [50,3,16,58]. On the other hand, sulfide oxidizing metabolism is significantly less efficient in fibroblasts and neurons [26]. In DS fibroblasts, where H<sub>2</sub>S levels are elevated as compared to healthy tissues, cellular bioenergetics and proliferation is impaired because of H<sub>2</sub>S-mediated inhibition of cytochrome C oxidase [39,40,52]. Pharmacological inhibition of CBS has recently emerged as a potential experimental therapeutic strategy for cancer and DS [58], and it is expected to induce opposite effects according to the disease model, namely inhibition or stimulation of cellular viability, respectively. However, the number of selective pharmacological tools and, especially, potentially clinically translatable CBS inhibitors is very limited.

A recent screen, on recombinant CBS, has identified a few potentially repurposable inhibitors, including benserazide (which is clinically used in many countries as one component of a two-component anti-Parkinson drug, Madopar) [12]. Another screen, conducted in a cell-based system (yeast) have discovered that disulfiram (a multifunctional pharmacological agent traditionally seen as an inhibitor of aldehyde dehydrogenase (ALDH) and a clinically used drug in the treatment of alcoholism), has cellular actions that are consistent with a CBS inhibitory effect in yeast model systems as well as in rodent DS models. In addition, disulfiram was able to suppress cognitive phenotypes in a mouse model of Down syndrome (Tg(CBS) mice) [34]. However, in a prior campaign, where all of the clinically used drugs – including disulfiram – were screened, disulfiram did not emerge as a significant direct inhibitor of the recombinant CBS enzyme [12]. The current study was designed to resolve this paradox. In particular, we have explored the possibility that potential bioconversion of disulfiram is necessary for its CBS inhibitory effect. The data presented in the current article are consistent with the hypothesis that disulfiram inhibits CBS in cellular environment via conversion to bis(N,N-diethyldithiocarbamate)-copper(II) complex (CuDDC), and the active principle of its action is, in fact, related to the complexed copper in this molecule. Accordingly, the data demonstrate that disulfiram and CuDDC exert cellular actions in cancer cells and DS cells that are similar to the effect of CBS deficiency and other, previously tested CBS inhibitors. Although disulfiram is not a direct CBS inhibitor, the current data suggest that disulfiram, CuDDC or disulfiram/copper

combinations may be future options for experimental therapeutic CBS inhibition *in vivo*.

## 2. Materials and methods

### 2.1. Materials

7-Azido-4-methylcoumarin (AzMC), bovine serum albumin (BSA), copper chloride (CuCl<sub>2</sub>), disulfiram, 5,5'-Dithiobis(2-nitrobenzoic acid) (DTNB), homocysteine, lactalbumin hydrolysate, S-(5'-adenosyl)-L-methionine (SAM), sodium diethyldithiocarbamate (DDC) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma/Aldrich Chemie GmbH (Munich, Germany). Pyridoxal 5'-phosphate (PLP) and cysteine (Cys) were obtained from Applichem (Darmstadt, Germany). Copper diethyldithiocarbamate (CuDDC) and zinc diethyldithiocarbamate (ZnDDC) were purchased from Tokyo Chemical Industry (Tokyo, Japan). GYY4137 from Cayman Chemical (Ann Arbor, Michigan, USA). Cell proliferation kit II [2,3-Bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide (XTT)] and cell proliferation ELISA 5-bromo-2'-deoxyuridine (BrdU) kit were purchased from Roche Diagnostics (Sigma-Aldrich Chemie GmbH: Munich, Germany). All other materials and reagents for cell culture were obtained from Thermo Fisher Scientific (Basel, Switzerland).

### 2.2. Cell culture

The human colorectal carcinoma cell line HCT116 (ATCC®, CCL-247™) was cultured in McCoy's 5A medium while Detroit 551 and Detroit 539 (human dermal fibroblasts from healthy and DS subjects, respectively) (LGC Standards, Wesel, Germany) were cultured in Advanced Dulbecco's Modified Eagle Medium/nutrient mixture F-12 (DMEM / F-12, 1:1; 1X), supplemented with 2 mM Glutamax™, and 0.1% lactalbumin hydrolysate. All the culture media were supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were grown in a humidified incubator at 37 °C and 5% CO<sub>2</sub> atmosphere.

### 2.3. Recombinant human CBS and CSE expression and purification

Recombinant full-length human CBS, CSE and 3-MST were purchased from GenScript (Piscataway, NJ, USA). Both CBS and CSE storage buffer contained 0.5 mM TCEP, thus favoring their reduced state.

### 2.4. Mouse liver homogenate

Female Balb/c mice were anesthetized under isoflurane flux and euthanized. All animal-related procedures performed were approved by the Swiss Federal Food Safety and Veterinary Office (license no. FR\_2018\_11). Liver tissue was homogenized in RIPA buffer supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail using Fisherbrand™ Bead Mill 4 Homogenizer set 120 s at 3 m/s. The resulting mixture was stirred overnight at 4 °C. Supernatant was collected after 15 min centrifugation at 17,000×g and 4 °C, and protein concentration was quantified with Pierce™ Coomassie Plus (Bradford) Assay Reagent, against BSA protein standard. The resulting absorbance was detected with an Infinite M200 Pro microplate reader (Tecan, Männedorf, Switzerland). All the reagents were purchased from Thermo Fisher (Basel, Switzerland).

## 2.5. Compound preparation

All compounds were freshly dissolved in DMSO (disulfiram and CuDDC) or MilliQ water ( $\text{CuCl}_2$  and DDC) to produce a stock solution 100 mM, which was used to prepare serial dilutions of each compound. Before cell treatments, compounds were diluted in the culture medium to yield a final concentration ranging from 0.1  $\mu\text{M}$  to 100  $\mu\text{M}$  (0.1% DMSO).

## 2.6. Detection of $\text{H}_2\text{S}$ generation in mouse liver homogenate and recombinantly expressed human enzyme CBS, CSE and 3-MST

$\text{H}_2\text{S}$  enzymatic generation from mouse liver homogenate, recombinant CBS, CSE or 3-MST were conducted as described [12,4]. Activity assays were carried out using black 96-well plate with flat bottom. For  $\text{H}_2\text{S}$  detection from tissue homogenate, the reaction mixture, in TRIS-HCl buffer pH 8.0, contained 13.5  $\mu\text{g}/\text{well}$  mouse liver homogenate, 5  $\mu\text{M}$  PLP, 500  $\mu\text{M}$  SAM and 10  $\mu\text{M}$  AzMC. Each well received 2  $\mu\text{l}$  of test compounds at increasing concentration, in a total assay volume of 200  $\mu\text{l}$ . The reaction was triggered by addition of 2 mM cysteine and 500  $\mu\text{M}$  homocysteine (final concentration). Enzymatic activity of the human recombinant full-length CBS was measured in the presence of 100  $\mu\text{M}$  SAM (1  $\mu\text{g}/\text{well}$ ) or CSE (5  $\mu\text{g}/\text{well}$ ) (without SAM), in otherwise identical assay conditions. For 3-MST activity, 5  $\mu\text{g}/\text{well}$  of recombinant 3-MST was incubated with the 3-MST substrate 3-mercaptopyruvate at final concentration of 1 mM; AzMC was used at the final concentration of 10  $\mu\text{M}$ . For all enzymatic assays, fluorescence (an index of  $\text{H}_2\text{S}$  production) was measured in kinetic mode for 2 h at 37 °C with an Infinite M200 Pro plate reader (Tecan, Männedorf, Switzerland), at  $\lambda_{\text{excitation}} = 365 \text{ nm}$  and  $\lambda_{\text{emission}} = 450 \text{ nm}$ , respectively. Control experiments aiming to evaluate the possible  $\text{H}_2\text{S}$ -scavenging effect of the test compounds were performed by employing the  $\text{H}_2\text{S}$  donor GYY4137 (2 mM final concentration) instead of the recombinant enzyme, using AzMC-aided  $\text{H}_2\text{S}$  detection as described above. Data were analyzed in Excel (Microsoft Corporation, Redmond, Washington, USA) and activity was estimated from the initial slope of the fluorescence over the time.

## 2.7. Determination of number of free thiol group in recombinantly expressed human enzyme CBS, CSE and 3-MST


Free protein thiols were quantitated with the DTNB method. Briefly, 900  $\mu\text{l}$  of enzyme sample (5  $\mu\text{M}$  in 100 mM phosphate buffer, pH 8.0) was dispensed in Eppendorf tubes and each supplemented with increasing concentrations of  $\text{CuCl}_2$  (0–50  $\mu\text{M}$ ), followed by 30 min incubation at room temperature (RT) in the absence of light. Next, samples received 100  $\mu\text{l}$  DTNB 10 mM and were further incubated for 30 min at RT in the absence of light. Spectra were typically acquired between 250 and 500 nm using a quartz cuvette and an Infinite M200 Pro spectrophotometer (Tecan, Männedorf, Switzerland). The 2-nitro-5-thiobenzoic acid anion formation was estimated by analysing absorbance values at 412 nm and using an extinction coefficient of  $14,150 \text{ M}^{-1} \text{ cm}^{-1}$ , as recommended by the manufacturer. Spectra of DTNB alone (blank) and protein samples prior to DTNB addition (intrinsic protein absorption at 412 nm) were also acquired. Number of free thiols were determined according to the following equation:

$$\text{freethiols} = \frac{\text{Abs}_{\text{protein+DTNB}} - \text{Abs}_{\text{protein}} - \text{Abs}_{\text{DTNB}}}{14,150 \times [E]}$$

where [E] is the enzyme concentration in the cuvette determined at 280 nm.


## 2.8. Detection of $\text{CuCl}_2$ and CuDDC interference with Cys and 3-MP

Assays were carried out in flat-bottom 96-well plates, in 100 mM phosphate buffer pH 8.0, using the Infinite M200 Pro plate reader



**Fig. 1.** Disulfiram (DSF) reaction with copper. The DSF's disulfide bond (S-S) is promptly reduced after cell intake thus producing diethylthiocarbamate (DDC), which is a strong chelator of transition divalent metal ions, such as copper (II).

(Tecan, Männedorf, Switzerland). Briefly, each well received 2 mM Cys or 3-MP and increasing concentration of  $\text{CuCl}_2$  (0–100  $\mu\text{M}$ ). After gently resuspension of the assay mixture, the plate was incubated for 30 min at 37 °C in the absence of light, followed by the addition of 50  $\mu\text{l}$  of 10 mM DTNB (2 mM final concentration), and further incubated for 10 min at RT and in the absence of light. The resulting mixture was diluted 1:5 in the same buffer in a final volume of 100  $\mu\text{l}$  and unreacted thiols were detected spectrophotometrically at 412 nm. In the case of CuDDC, the presence of thiolic moieties within its structure (Fig. 1) raised an issue of incompatibility with the DTNB method. Therefore, in order to detect a possible instability of this complex in the presence of Cys or 3-MP, it was exploited its characteristic absorption at 450 nm [32]. Briefly, each well received 10  $\mu\text{M}$  CuDDC and increasing concentrations of Cys or 3-MP (0–2 mM). After gently resuspension of the assay mixture, the plate was incubated for 30 min at 37 °C in the absence of light. Spectra were



**Fig. 2.** Effect of disulfiram, CuDDC, CuCl<sub>2</sub> and DDC on AzMC signal. Assays were carried out on mouse liver homogenate, isolated full-length human CBS, isolated human CSE and isolated 3-MST. Compounds were counterscreened in the presence of the H<sub>2</sub>S-donor GYY4137 for their ability to scavenge H<sub>2</sub>S. Where available, a dashed line with the corresponding IC<sub>50</sub> value is also shown. Data represent values of n = 5 independent experiments (mean ± SD).

recorded from 350 to 600 nm.

### 2.9. Measurement of cell proliferation

Cells were typically seeded in Corning® Costar® TC-treated flat-bottom 96-well plates in a final volume of 100 µl and incubated in a humidified incubator at 37 °C and 5% CO<sub>2</sub> atmosphere, unless otherwise stated. HCT116 cells were seeded at a cell density of 6,000 cells/well and incubated overnight. Detroit 551 and 539 cell lines were seeded at a density of 20,000 cells/well and incubated for 2 h. In both cases incubation was followed by a 24-h treatment with test compounds. Subsequently, cells were incubated with 10 µM BrdU labelling solution for 4 h at 37 °C and 5% CO<sub>2</sub>. This assay relies on the ability of proliferating cells to incorporate BrdU, a pyridine analogue, in place of thymidine into the newly synthesized DNA. After removing the culture medium, DNA denaturation-fixation was performed, followed by incubation with the anti-BrdU antibody. Subsequently, the colorimetric substrate reaction was measured. Absorbance was measured at 450 nm with 690 nm as the reference wavelength using an Infinite M200 Pro plate reader (Tecan, Männedorf, Switzerland). The absorbance values directly correlate to the amount of DNA synthesized, and therefore is function of the number of proliferating cells in the respective microcultures.

### 2.10. Measurement of cell viability

Following cell treatment (as described above), HCT116 cells were further incubated for 2 h with 0.5 mg/ml MTT. The converted formazan dye was dissolved in DMSO and the absorbance was measured at 570 nm and 690 nm (reference wavelength) with an Infinite 200 Pro plate reader (Tecan, Männedorf, Switzerland). Detroit 551 and 539 cell viability were

measured with XTT assay as described [40]. Each micro-well received 50 µl of XTT labelling reagent and 1 µl of electron coupling reagent, yielding final XTT concentration of 0.3 mg/ml. Cells were incubated with the XTT labelling mixture for 6 h at 37 °C. Plates were then gently shaken for 5 min and absorbance was measured at 492 and 690 nm (reference wavelength) using an Infinite M200 Pro plate reader (Tecan).

### 2.11. Detection of H<sub>2</sub>S production in live cells

Cells were plated in in flat-bottomed Thermo Fisher Nunc® black 96-well plates and treated as described above. After the treatment, culture medium was replaced with HBSS buffer supplemented with AzMC 10 µM (Detroit 551 and Detroit 539) and further incubated for 1 h. The AzMC signal was acquired at λ<sub>excitation</sub> = 365 nm and λ<sub>emission</sub> = 450 nm an Infinite M200 Pro plate reader (Tecan, Männedorf, Switzerland). Visualization of H<sub>2</sub>S-generation in HCT116 living cells was performed as previously described [40,4]. Briefly, 30,000 HCT116 cells were seeded in a Lab-Tek II chamber coverglass system and incubated at 37 °C and 5% CO<sub>2</sub> for 48 h, followed by acute treatment with test compounds (2 h). After the treatment, culture medium was replaced with 100 µM AzMC in HBSS buffer and further incubated for 1 h. Cells were washed in HBSS buffer and dye's specific fluorescence was visualized using Olympus CKX53 inverted microscope and images were captured with Olympus SC50 digital camera and cellSens imaging software (Olympus, Volketswil, Switzerland). Images were then analyzed with the ImageJ software (v. 1.8.0; NIH, Bethesda, Maryland, USA).

### 2.12. Bioenergetic analysis in liver cells

The Seahorse XFe-24 flux analyzer (Agilent Technologies, Santa

**Table 1**

IC<sub>50</sub> (μM) values of CuDDC and CuCl<sub>2</sub>. Values were calculated using non-linear fitting equation using GraphPad Prism software. Mean ± SEM values (n = 5).

Compound	Mouse liver homogenate	CBS	CSE	3-MST	GY4137
CuDDC	0.6 ± 0.2	1.2 ± 0.4	1.0 ± 0.2	>100	1.2 ± 0.4
CuCl <sub>2</sub>	0.4 ± 0.2	0.6 ± 0.4	0.6 ± 0.2	11.2 ± 3.5	1.1 ± 0.3

Clara, California, USA) was used to estimate mitochondrial respiration of Detroit 551 and Detroit 539 cell lines as previously described [37,39]. Cells were seeded in Seahorse XFe-24 Cell Culture Microplates at a 20,000 cells/well density in a total volume of 200 μl, incubated for 2 h, followed by treatment for 24 h. Next, culture medium was replaced with Seahorse XF DMEM, supplemented with 20 μM glutamine, 10 μM pyruvate and 1 mM glucose (final concentration). The microplate was then incubated in a CO<sub>2</sub>-free incubator at 37 °C for 1 h, to allow temperature and pH equilibration, as recommended by the manufacturer. The assay protocol consisted in two measurements of basal values of oxygen consumption rate (OCR), followed by the injection of 1 μM oligomycin, used to evaluate ATP generation rate. Subsequently, the mitochondrial oxidative phosphorylation uncoupler FCCP (2 μM), was employed to estimate maximal mitochondrial respiratory capacity. Eventually, 0.5 μM of rotenone and antimycin A were injected to inhibit the electron flux through the complex I and III, respectively, aiming to detect the extra-mitochondrial OCR. Data were analyzed with Wave (v. 2.6; Agilent Technologies, Santa Clara, California, USA) and graphed with GraphPad Prism 8 (GraphPad Software Inc.; San Diego, California, USA).

### 2.13. Statistical analysis


Data are shown as mean ± SEM of at least five independent experiments, unless otherwise stated. Differences among data are considered significant for p values < 0.05. Two-way ANOVA, followed by post-hoc Bonferroni's multiple-comparison test, was used to compare Detroit 551 to Detroit 539. Alternatively, ordinary one-way ANOVA, followed by post-hoc Bonferroni's multiple-comparison test, was employed to identify differences within HCT116 cell line as compared to non-treated control. Statistical calculations were performed using GraphPad Prism 8 (GraphPad Software Inc.; San Diego, California, USA).

## 3. Results

### 3.1. Effect of disulfiram, DDC, CuCl<sub>2</sub> and CuDDC on mammalian H<sub>2</sub>S generation

In cellular milieu, disulfiram has been shown to be reduced to diethyldithiocarbamate (DDC), which is considered its major metabolite [20]. DDC is a very strong chelator of transition divalent metal ions, mainly copper(II) (Cu) and zinc. Intracellularly, DDC can therefore, rapidly react with copper to form a complex known as cupric diethyldithiocarbamate (CuDDC) [20,9,29,8] (Fig. 1). In order to test the effect of disulfiram, DDC, CuCl<sub>2</sub> and CuDDC on H<sub>2</sub>S enzymatic generation from an intact tissue, were firstly carried out activity assays in a mouse liver homogenate, using the selective fluorescent H<sub>2</sub>S probe AzMC. As shown in Fig. 2 and Table 1, disulfiram and DDC produced a weak inhibitory effect on H<sub>2</sub>S generation (approx. 10% inhibition at the highest concentration, 100 μM tested), while CuDDC and CuCl<sub>2</sub> concentration-dependently and markedly reduced the AzMC signal with half maximal inhibitory concentrations (IC<sub>50</sub>) of ~ 0.6 μM and ~ 0.4 μM, respectively.


To investigate whether this effect was restricted to CBS or involved also the others H<sub>2</sub>S producing enzymes, H<sub>2</sub>S detection assays were



**Fig. 3.** Binding of CuCl<sub>2</sub> to cysteine residues of CBS, CSE and 3-MST. Assays were carried out on isolated full-length human CBS, isolated human CSE and isolated 3-MST in the presence of increasing concentration of CuCl<sub>2</sub>. Data represented refers to at least n = 3 independent experiments (mean ± SD).

carried out in presence of recombinant CBS, CSE and 3-MST. For both CBS and CSE, neither disulfiram, nor DDC had any inhibitory effect on the AzMC signal, whereas the IC<sub>50</sub> of CuDDC and CuCl<sub>2</sub> was 1 μM and 0.6 μM, respectively. In contrast, 3-MST-derived H<sub>2</sub>S production was inhibited by CuCl<sub>2</sub> with an IC<sub>50</sub> ~ 11 μM. The inhibitory effect of disulfiram and CuDDC on 3-MST-derived AzMC signal approached (but did not quite reach) 50% inhibition even at the highest concentration (100 μM) of the compounds tested (i.e. IC<sub>50</sub> > 100 μM).

Since copper itself is not only known as a potent inhibitor of CBS and CSE [35,6,12] but it is also known to directly interact with various sulfur species [12,51], the question arose as to whether the observed AzMC signal reduction by CuDDC and/or CuCl<sub>2</sub> was due to a direct inhibition of the enzymatic activity or H<sub>2</sub>S scavenging may have also contributed. The H<sub>2</sub>S producing enzymes were therefore replaced with GYY4137, an organic H<sub>2</sub>S donor that releases H<sub>2</sub>S at a slow, steady rate [28] and the effect of the various compounds on the AzMC signal was recorded. While disulfiram and DCC exerted no inhibitory effect on the GYY4137-generated H<sub>2</sub>S signal, both CuDDC and CuCl<sub>2</sub> significantly reduced the



**Fig. 4.** Interference of CuCl<sub>2</sub> or CuDDC with enzyme substrates. A) Interaction of 2 mM cysteine or 3-MP with increasing concentrations of CuCl<sub>2</sub> by measuring free thiols with the DTNB method, B) interaction of 10 μM CuDDC at increasing concentration of cysteine or 3-MP, as evaluated by recording changes on CuDDC absorption at 450 nm. C) Representative experiment of CuDDC spectral changes in presence of increasing concentration of cysteine. Data represent values of n = 3 independent experiments (mean ± SEM). \*\*p < 0.01 indicate significant differences compared to control.

signal, with IC<sub>50</sub> values of ~ 1.2 μM and ~ 1.1 μM, respectively.

The enzymatic activity of the three H<sub>2</sub>S producing enzymes is regulated by the presence of redox-sensitive cysteines [46]. This prompted us to investigate whether a direct interaction of copper with protein exposed cysteine residues could play a role in their enzymatic inhibition. Free/accessible thiols were determined for CBS, CSE and 3-MST with the DTNB method and protein-copper binding was assessed by evaluating any changes in the number of free cysteine residues. CBS was the only one having a significant propensity to bind copper at the lowest concentration tested (0.1 μM), while both CSE and MST showed a significant decrease in free thiols number only at 10 μM CuCl<sub>2</sub>. Particularly, untreated CBS displayed 11.6 ± 0.4 free cysteine residues, and after treatment with 0.1 μM CuCl<sub>2</sub> 10.9 ± 0.3 residual free cysteine residues (p < 0.05) were detected, suggestive of the formation of one Cu-S bond (Fig. 3A). The susceptibility of protein free cysteines to be targeted by copper ions was evaluated only against CuCl<sub>2</sub>, as in the case of CuDDC the presence of thiolic moieties would interfere with the DTNB method.

Given the marked reactivity showed by copper ions against thiolic species, we wondered whether this could be translated into an interference of the catalytic activity through a direct interaction with enzymes substrates, namely Cys and 3-MP. With the aim to address this question, 2 mM Cys or 3-MP were incubated with increasing concentrations of CuCl<sub>2</sub>. As shown in Fig. 4A, free Cys levels were reduced by

**Table 2**

H<sub>2</sub>S production in mouse liver homogenate in presence of increasing concentration of zinc complexed with diethyldithiocarbamate (ZnDDC) or free zinc ions. Activity is expressed as % of control. Mean ± SEM values (n = 5).

Compound	Activity (% of control)		
	1 μM	10 μM	100 μM
ZnDDC	100 ± 0.2	100 ± 0.2	100 ± 0.2
ZnCl <sub>2</sub>	100 ± 0.2	100 ± 0.2	100 ± 0.2
1 μM CuCl <sub>2</sub> + [c] μM disulfiram	0	4 ± 0.3	56 ± 0.4
1 μM CuCl <sub>2</sub> + [c] μM DDC	0	50 ± 0.4	84 ± 0.2


copper in a concentration-dependent mode, overall accounting for an IC<sub>50</sub> of ~ 0.3 μM. With respect to 3-MP, the interaction with copper exhibited a biphasic profile. Although the residual free thiol levels dropped down to ~50% already at 0.1 μM CuCl<sub>2</sub>, higher concentrations of copper appeared to have a much smaller effect of 3-MP. With the aim to evaluate the interference of CuDDC with Cys and 3-MP a different experimental approach was adopted, as the thiolic moieties of CuDDC are reactive towards DTNB, thus possibly leading to artifacts. The complex of copper with DDC displays a yellow color with a characteristic absorption peak at 450 nm which is not exhibited by copper ions or DDC alone [32]. It was, therefore, exploited this feature to evaluate the stability of the complex at increasing concentration of Cys or 3-MP (Fig. 4C). As shown in Fig. 4B, CuDDC appeared to be relatively stable even at 2 mM Cys or 3-MP.

ZnDDC, another metal complex of DDC, exerted no inhibitory effect on enzymatic CBS generation (Table 2), indicating that it was the copper moiety in CuDDC that was responsible for its pharmacological effects described above. As expected, the inhibitory effect of CuCl<sub>2</sub> on CBS activity was reduced with increasing concentrations of disulfiram or DDC, suggestive of the formation of a copper complex molecule (Table 2).

From the above data, we can conclude that disulfiram is not a direct inhibitor of CBS, but its metabolite CuDDC is (and its potency is comparable to that of free copper (II) ions). Moreover, both CuDDC and copper also directly interact with H<sub>2</sub>S to catalyze its decomposition. The complexed form CuDDC appears to be slightly less potent than free copper as an inhibitor of the CBS-derived AzMC signal. Indeed, copper, but not CuDDC, interacts with Cys and, to a less extent, with 3-MP, thus reducing enzymatic activity via direct interference with the reaction substrates. We hypothesize that this difference in potency is due to the fact that in CuDDC the copper is present in a complexed form and may be less reactive towards protein cysteine residues, as well as Cys substrate, thus CuDDC's effects relies on its ability to release copper ions *in situ*. It is conceivable that the slight inhibition by disulfiram of H<sub>2</sub>S generation that we have noticed in the liver homogenates may be due to the formation of CuDDC in the cellular environment, which contains redox-active components as well as copper. Interestingly, free copper (II) ions exerted a ~ 20 fold weaker effect on 3-MST-derived AzMC signal than on CBS-derived AzMC signal, while CuDDC only exerted a weak inhibitory effect, thus suggesting a higher propensity of copper to interfere with the catalytic activity of CBS and CSE than 3-MST.

### 3.2. CuDDC reduces intracellular H<sub>2</sub>S levels and proliferation of HCT116 cells

HCT116 cells express high levels of CBS (as well as 3-MST) and utilize H<sub>2</sub>S to support their bioenergetics and proliferation [54,41]. As shown in Fig. 5, disulfiram did not affect H<sub>2</sub>S generation in HCT116 cells, while CuCl<sub>2</sub> exerted a partial inhibitory effect at the highest concentration tested. On the other hand, CuDDC exerted a concentration-dependent (and, at 3 and 10 μM, near-complete) inhibitory effect on the AzMC signal (Fig. 5). From the technical point of view, data above referred were obtained after an incubation period of 2 h since prolonged exposure to CuDDC caused strong morphological changes even at low



**Fig. 5.** H<sub>2</sub>S detection on HCT 116 cells. A) Cells were treated with 3 μM Disulfiram, CuDDC or CuCl<sub>2</sub> for 2 h and intracellular H<sub>2</sub>S was detected AzMC fluorescent probe. Control received only vehicle. B-D) Quantification of AzMC signal at increasing concentration of test compounds. Data represent values of n = 3 independent experiments (mean ± SEM). \*p < 0.05 and \*\*p < 0.01 indicate significant differences compared to control (non treated) cells.

concentration and thus live cell imaging was not performed.

While disulfiram did not have any significant effect on cell proliferation or viability, CuCl<sub>2</sub> decreased both of these parameters at the highest concentration used in this experiment (100 μM) (Fig. 6). A potent effect was observed with CuDDC, which exerted a concentration-dependent inhibitory effect both on cell proliferation and on viability with an IC<sub>50</sub> of approximately 0.3 μM, possibly because of impairment of mitochondrial metabolism, as suggested by the MTT assay (Fig. 6).

These data indicate that CuDDC is a fairly potent inhibitor of cellular H<sub>2</sub>S generation, and the inhibitory effect of cancer cell proliferation and viability may be consistent with the known role of H<sub>2</sub>S in cancer cells. Nevertheless, additional pharmacological actions of CuDDC may also contribute to the observed effects (See: Discussion). The lack of disulfiram's effect may be attributed to either low cellular uptake of this compound into the tumor cell, lack of intracellular conversion to CuDDC in this cell type (which may be cell-type-dependent, see below), or lower content of endogenous copper. The lack of CuCl<sub>2</sub>'s effect is most likely due to its low cell penetration.

### 3.3. Disulfiram and CuDDC suppress intracellular H<sub>2</sub>S levels in DS fibroblasts and restore their viability and proliferation rate

DS fibroblasts exhibit a significant overproduction of H<sub>2</sub>S, contributing to impaired viability, proliferation rate and bioenergetics [39,40]. As shown in Fig. 7A, cells were incubated for 24 h in the presence of the test compounds, at a concentration consistent with the increase of cell viability and proliferation rate (see below). Disulfiram, while not exerting any apparent effect on healthy control cells, significantly inhibited the AzMC signal in DS cells, already at the lowest concentration (0.1 μM) tested. CuDDC exerted a similarly potent inhibitory effect, while CuCl<sub>2</sub> was without any effect (Fig. 7).


Disulfiram exerted a bell shaped-effect on viability and proliferation rate in DS cells; in the submicromolar concentrations it improved these parameters so that the proliferation rate and the viability of these DS cells approximated those of the healthy control fibroblasts. However, the drug began to show inhibitory and cytotoxic effects in the higher concentration range tested (1–10 μM) (Fig. 8). Similar to the findings seen in HCT116 cells, copper alone did not display any effect in DS cells, whereas, CuDDC improved viability and proliferation of DS cells at 0.1–0.3 μM, but not at the higher concentration tested (1 μM) (Fig. 8).

In contrast to DS cells, in normal control fibroblasts, none of the compounds tested had any effect on the (low baseline) H<sub>2</sub>S production; disulfiram (at 3–10 μM) and CuDDC (at 1 μM) suppressed cell viability and proliferation, probably by affecting pathways and cellular targets other than CBS or H<sub>2</sub>S (see: Discussion).

The increase in cell viability, as assayed with XTT method, accounts for an increased mitochondrial metabolism (Fig. 8). With the aim to clarify this aspect, bioenergetic measurements were carried out on cells treated with test compounds at a concentration in line with cell viability and proliferation rate increase. Data shown in Fig. 9 indicate that disulfiram improves the various parameters of mitochondrial respiration and cellular oxygen consumption in DS cells, without affecting control cells, while neither CuDDC nor CuCl<sub>2</sub> exerted any significant effect on these parameters.

The data presented in the prior section indicate that in DS cells, disulfiram and CuDDC exert potent pharmacological effects. Already at low concentrations, disulfiram and CuDDC both inhibit H<sub>2</sub>S production and improve cell viability. We have also noticed previously that other inhibitors of H<sub>2</sub>S biosynthesis (e.g. the CBS inhibitor aminooxyacetate and the 3-MST inhibitor HMPSNE) are very potent in DS cells [39,40]; it is thus possible that this cell type has a high permeability for various pharmacological agents. The effects of disulfiram and CuDDC are similar






**Fig. 6.** Effect of disulfiram, CuDDC and CuCl<sub>2</sub> on HCT 116 cells viability and proliferation. Cells were treated over 24 h at increasing concentration of test compounds and cellular viability and proliferation were evaluated with MTT and BrdU method, respectively. Data represent values of n = 5 independent experiments (mean ± SEM). \*\*p < 0.01 indicates significant differences as compared to control (non treated) cells.

to the above-mentioned inhibitors, in that at low concentrations they enhance cell viability and proliferation, while at higher concentrations an inhibitory effect becomes evident [39,40]. We interpret the current findings as follows: in DS fibroblasts (which exhibit defects in their mitochondrial bioenergetic function and have difficulties to maintain cellular functions due to their impaired cellular bioenergetic status), take up disulfiram from the extracellular space, which, in turn, inhibits intracellular H<sub>2</sub>S production and, consequently improves cellular bioenergetics and proliferation. However, unexpectedly, in this cell type administration of CuDDC failed to improve cellular bioenergetic parameters. As expected, copper *per se* (similar to the situation in HCT116 cells) does not enter the DS cells (or the control fibroblasts) and does not exert detectable effects on H<sub>2</sub>S production or cell viability or cell function.

#### 4. Discussion

The main findings of the current report can be summarized as follows: (1) disulfiram does not exert any significant direct inhibitory effect on any of the recombinant H<sub>2</sub>S-producing enzymes in cell-free conditions; (2) disulfiram exerts a slight inhibitory effect on H<sub>2</sub>S generation in liver homogenates, presumably due to its conversion to active metabolites; (3) disulfiram does not significantly inhibit H<sub>2</sub>S production in

HCT116 colon cancer cells, but it does inhibit H<sub>2</sub>S production in DS fibroblasts (presumably illustrating a cell-type-dependent uptake and/or metabolism); (4) accordingly, disulfiram does not have any functional effects in HCT116 cells, but it exerts a bell-shaped effect, a stimulatory effect at low concentrations and an inhibitory effect at higher concentrations on the viability and proliferation of DS cells (an effect, that is characteristic of inhibitors of H<sub>2</sub>S biosynthesis in this cell type); (5) the main metabolite of disulfiram, DDC does not inhibit any of the H<sub>2</sub>S producing enzymes and neither does it scavenge H<sub>2</sub>S; (6) the copper complex of DDC (CuDDC) is a potent inhibitor of CBS and CSE, as well as a scavenger of H<sub>2</sub>S; (7) CuDDC inhibits H<sub>2</sub>S production both in HCT116 cells and in DS fibroblasts and exerts the expected functional effects (inhibitory effect in HCT116 cells and bell-shaped effects in DS cells on proliferation and viability); (8) the inhibitory effect of CuDDC on H<sub>2</sub>S-related parameters is due to its complexed copper atom; another metal complex (ZnDDC) does not inhibit the H<sub>2</sub>S/AzMC signal; (9) in line with prior findings, the current experiments confirm that free copper (II) is a potent inhibitor of the CBS and CSE-derived AzMC signal (and a weaker inhibitor of 3-MST-derived AzMC signal) and it is also able to directly interact with enzyme substrates Cys and 3-MP, as well as with chemically generated H<sub>2</sub>S; (10) copper (II) binds CBS via formation of a Cu-S bond with a solvent accessible cysteine residue and possibly playing a role in CBS inhibition mechanism; (11) the *in vitro* effects of free copper




**Fig. 7.** H<sub>2</sub>S detection on Detroit 551 (CC) and Detroit 539 (DSC) cells. A) Cells were treated with 0.1 μM disulfiram, 0.3 μM CuDDC or 3 μM CuCl<sub>2</sub> for 24 h and intracellular H<sub>2</sub>S was detected AzMC fluorescent probe. Control received only vehicle. B-D) Quantification of AzMC signal upon treatment with increasing concentration of disulfiram, CuDDC or CuCl<sub>2</sub> for 24 h. Data represent values of n = 5 independent experiments (mean ± SEM). \*\*p < 0.01 indicates a significant increase in fluorescence in DSCs vs. CCs; ##p < 0.01 indicates a significant inhibitory effect of the test compound on cellular H<sub>2</sub>S levels in treated vs. non-treated DSCs.

on H<sub>2</sub>S homeostasis cannot be recapitulated in cultured cells, presumably due to its low cellular uptake; and, finally, (12) CuDDC, unexpectedly (and in contrast to disulfiram), does not improve cellular bioenergetics in DS cells, even though it improves their viability and proliferation. The explanation for this last finding and discrepancy is currently unclear.

In mammals, the reverse transsulfuration pathway (TS) is a crucial pathway regulating the generation of cysteine from homocysteine, through two sequential reactions catalyzed by the cytosolic pyridoxal 5'-phosphate (PLP)-dependent enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE), both producing hydrogen sulfide (H<sub>2</sub>S) as side product [47,53]. One of the possible metabolic routes of the resulting cysteine is its bioconversion into 3-mercaptopyruvate (3-MP), a substrate for the cytosolic and mitochondrial enzyme 3-MST, which, in turn, generates pyruvate and H<sub>2</sub>S as end-products [56,23]. Dysregulation of sulfur metabolism has deep implications in human pathophysiology, which so far have been broadly documented in cancer biology, as witnessed by the massive body of literature associating CBS upregulation with oncological diseases [50,3,16,58]. Increased H<sub>2</sub>S levels has been found to stimulate cellular bioenergetics, migration, proliferation and invasion, first shown in HCT116 colon cancer cell line, which constitutively express elevated CBS levels [54] and subsequently expanded into many cell types [50,58]. Conversely, in the brain, where

sulfide detoxification enzymatic machinery is less active [26], H<sub>2</sub>S-overproduction may result in neuronal toxicity. Accordingly, high CBS and 3-MST expression in DS has been postulated to contribute to some of the clinical features of DS [39,40,21,52]. Indeed, brain tissues of DS patients were shown to be enriched in CBS content, and particularly, in older individuals it co-localizes with senile plaques [19]. Recently, working on fibroblasts of DS patients (Detroit 539) vs healthy control (Detroit 551), we have reported that DS cells display a decreased electron flux along the electron transport chain and this correlated with high H<sub>2</sub>S levels, thus suggesting that a H<sub>2</sub>S-induced inhibitory effect on cytochrome C oxidase may play a role in DS-associated mitochondrial impairment [39]. Interestingly, DS cells proliferation and mitochondrial function was significantly improved after CBS gene silencing or its pharmacological inhibition with aminooxyacetic acid (AOAA), thus identifying CBS as a potential target for therapy [39]. However, despite several medium-throughput academic screening campaigns conducted over the years, a potent and selective CBS inhibitor suitable for pharmacological application is not yet available [58].

Recently, Marechal et al. carried out a cell-based high-throughput drug screening on a *S. cerevisiae* model overexpressing *CYS4*, the yeast homolog of CBS, and identified disulfiram, as an inhibitor of the transsulfuration pathway [34]. A follow-up *in vivo* study in DS mice showed significant behavioral improvements after treatment with disulfiram




**Fig. 8.** Effect of disulfiram, CuDDC and CuCl<sub>2</sub> on Detroit 551 (CC) and Detroit 539 (DSC) viability and proliferation. Cells were treated over 24 h at increasing concentration of test compounds and cellular viability and proliferation were evaluated with XTT and BrdU method, respectively. Data represent values of  $n = 5$  independent experiments (mean  $\pm$  SEM). \*\* $p < 0.01$  indicates a significant decrease in cell viability or proliferation rate of DSCs vs. CCs; ## $p < 0.01$  indicates a significant increase of viability or proliferation rate of treated vs non-treated DSCs.  $\partial p < 0.05$  and  $\partial\partial p < 0.01$  indicate the significant increase of viability or proliferation rate of treated vs non treated CCs.

[34]. Although these data supported the hypothesis that disulfiram, in some way interferes with CBS activity, a direct inhibition was unlikely due to two issues (1) after cellular absorption disulfiram is rapidly bioconverted to its thiolic cognate (DDC) and to other metabolites [21,25] and (2) disulfiram is not a direct inhibitor of recombinant CBS [12]. These findings and considerations stimulated the current experiments, in order to explore the potential underlying biochemical mechanisms of disulfiram's action on H<sub>2</sub>S homeostasis. As shown in the Results section and summarized in the first paragraph of the Discussion section, the most likely explanation for disulfiram's inhibitory action on H<sub>2</sub>S production is that the drug is converted to CuDDC, which, in turn, inhibits H<sub>2</sub>S generation. In mammals, intracellular labile pools of bioavailable copper are stored in endosomes and lysosomes and their export to the cytosol is regulated by the membrane protein Cu transporter protein (Ctr) [44,2]. Particularly, it has been postulated that the biological effect of disulfiram (and/or DDC) can be at least in part explained by its ability to induce Ctr-independent copper (exogenous and endogenous) migration across biological membranes [1]. Here we show that the effects of disulfiram treatment are tissue dependent, likely because of different efficiency in cellular uptake and/or bioconversion to DDC. Moreover, it is conceivable that the result on endogenous copper mobilization is translated in a more pronounced biological response in tissues where copper content is higher, namely liver and brain [2]. We report that one of the possible consequences of intracellular copper mobilization is the


inhibition of CBS and CSE thereby suppressing intracellular H<sub>2</sub>S levels and exerting biological effects that are consistent with (and are expected from) the suppression of cellular H<sub>2</sub>S levels.

Mechanistically, the copper-dependent inhibition of CBS and CSE could be viewed as a sum of three factors: a) direct interaction with the enzyme, b) direct scavenging of H<sub>2</sub>S, and c) depletion of the substrate Cys by free copper ions. Among the three enzymes examined only CBS exhibited propensity to directly binding copper at a concentration below the IC<sub>50</sub>. Niu et al. have recently shown that the CXXC motif situated in CBS central domain is a redox sensitive center and its reduction induces ~3-fold increase of the enzymatic activity [38]. Intriguingly, many copper-dependent enzymes display a conserved CXXC motif for metal binding [7], hence it may be speculated that copper binding to CBS involves the CXXC motif. By contrast, we did not detect any interaction below the IC<sub>50</sub> value between copper and CSE, which shows four exposed cysteine residues involved two CXXC motifs and to which no regulatory function has been yet attributed [38,46].

Given the pronounced propensity of copper (and CuDDC) to directly interact with H<sub>2</sub>S, the weak inhibitory effect towards 3-MST-dependent H<sub>2</sub>S generation was somewhat unexpected. This apparent discrepancy is partly reconciled by the lack of direct interaction of copper with 3-MST (at low concentrations) together with the inability of copper to fully deplete 3-MP, by contrast to Cys. Moreover, differently from CBS and CSE, 3-MST's canonical reaction takes place in the presence of a sulfur



**Fig. 9.** Effect of disulfiram, CuDDC and CuCl<sub>2</sub> on Detroit 551 (CC) and Detroit 539 (DSC) mitochondrial respiration. Cells were treated over 24 h with 0.1 μM disulfiram, 0.3 μM CuDDC or 3 μM CuCl<sub>2</sub>. A) Basal respiration; B) Maximal respiration; C) ATP production; D) Spare Respiratory Capacity; E-K) Representative experiments showing mitochondrial respiration profile of Detroit 551 cells and Detroit 539 upon treatment with DSF, CuDDC and CuCl<sub>2</sub> as compared with non-treated cells. Data represent values of n = 5 independent experiments (mean ± SEM). \*p < 0.05 and \*\*p < 0.01 indicate significant decreases in cell viability or proliferation rate of DSCs vs. CCs; #p < 0.05 indicates a significant increase of cell viability or proliferation rate of treated DSCs vs. non-treated DSCs.



**Fig. 10.** Effect of disulfiram and its metabolite CuDDC on the  $H_2S$  system in cancer and Down's syndrome cell models. In colon cancer cells, the excess of  $H_2S$  supports cellular bioenergetics. Here, sulfide:quinone oxidoreductase (SQR) couples sulfide detoxification with energy production. *Vice versa*, in fibroblasts, where the sulfide oxidizing system is less represented, an increment  $H_2S$  levels may result in mitochondrial impairment because of cytochrome c oxidase (CcOX) inhibition. Disulfiram, through its metabolite CuDDC lowers intracellular  $H_2S$  levels through inhibition of cystathionine  $\beta$ -synthase and direct  $H_2S$  scavenging. This results in reduction or increase of cell viability and proliferation in colon cancer and DS fibroblasts, respectively. Disulfiram, through its metabolite CuDDC, lowers intracellular  $H_2S$  levels through inhibition of its biosynthesis, thus resulting in decrease or increase of cell viability in cancer and Down's syndrome fibroblasts, respectively.

acceptor such as cysteine, which leads to the formation of a persulfidated intermediate (Cys-SSH) instead of  $H_2S$  (which is then released through Cys-SSH non-enzymatic degradation) [59]. Herein, 3-MST activity was performed in the absence of a sulfur acceptor, a condition in which 3-MP itself likely works as a sulfur acceptor, thus producing 3-MP-SSH. The lower affinity of copper for 3-MP and, by extension 3-MP-SSH, as compared to  $H_2S$  may represent a further explanation of the weak effect of copper towards 3-MST activity.

The *in vitro* findings in DS fibroblasts presented in the current article are completely in line with the recently reported beneficial effects of disulfiram in DS rodent models [34]. However, potential pharmacological effects of disulfiram (or its metabolites) on other molecular targets cannot be excluded (see below).

Likewise, the findings with CuDDC in HCT116 cells are consistent with the role of  $H_2S$  in the maintenance of cancer cell viability and proliferation; a molecule that is a potent inhibitor of CBS and/or is a potent scavenger of  $H_2S$  would be expected to reduce cancer cell viability; similar effects were previously seen with other inhibitors of various  $H_2S$  producing enzymes in various cancer cells (reviewed in [50,3,58]). In fact, the antitumor effects of disulfiram and/or CuDDC are well known in the literature, although the mechanisms which have been previously attributed to these effects are diverse (and, up to this point, have not included the  $H_2S$  system). According to one line of thoughts, the effects of disulfiram are due to the *chelation of copper*, because when cellular copper levels are reduced, the cells have a defect in maintaining Cu-dependent chaperone proteins, Cu-binding ceruloplasmin, and various Cu-modulated enzymes like superoxide dismutases (SOD), which, in turn, diminishes their viability and makes them more susceptible to anticancer chemotherapeutic agents (reviewed in [30,44]). According to another line of thinking, the anticancer effects of disulfiram are dependent on the *presence of copper* in the cell, at least in part due to disulfiram's ability to chelate copper as CuDDC complex [49,1]. In fact, a recent study shows that the anticancer effect of disulfiram can be prevented by pretreatment of the cells with the copper chelator tetrathiomolybdate [10]. For instance, CuDDC has been shown to promote reactive oxygen species (ROS) generation; in addition, it was found to inhibit the ubiquitin-proteasome system, the P-glycoprotein multidrug efflux pump (thereby improving cancer multidrug resistance), suppressing the activation of NF- $\kappa$ B (thereby affecting pro-inflammatory and proliferative signalling), ultimately not only affecting the primary tumor but also cancer cell stemness and cancer metastasis [11,24,13,57]. It is clear that these effects are multiple, and this is not

entirely unexpected, if we view CuDDC as a "ballistic missile with a copper 'warhead'" that is able to penetrate the target cell or may be even directly formed inside the target cell. If the principal mode of CuDDC' action involves copper chemistry, then we can expect that many enzymes will be susceptible to inhibition, and this is, indeed the case. CuDDC may owe its anticancer effect due to interaction with ALDH, which has been shown to be upregulated in different tumor types, being involved in the stimulation of cancer metabolism and drug resistance, possibly through the biosynthesis of retinoic acid [42]. Copper itself has been shown to play a role in tumor angiogenesis [31], and patients affected by different types of cancer (including colon cancer) displayed increased serum copper content [33]. As a result, copper chelation has been suggested to be a possible adjuvant in cancer therapy, to be associated with traditional chemotherapy. Indeed, in addition to CuDDC, other copper chelating agents may also exert beneficial effects in cancer treatment [15,5], thus possibly recapitulating a similar effect on CBS and CSE. Though having a larger dataset including intracellular copper levels and mobilization of cellular copper stores would offer a further insight on the mechanism of action of disulfiram and CuDDC. Certainly, disulfiram and/or CuDDC mode of action is the result of the interference with different metabolic pathways, with overlapping effects, eventually culminating with tissue-dependent outcome. In many cancer cell types  $H_2S$  has been shown to act as a metabolic fuel [50], therefore the anticancer effect of CuDDC could be summarized by reduction of  $H_2S$  bioavailability. Conversely, in fibroblasts, where the sulfide detoxifying machinery is less represented, high  $H_2S$  levels may represent a threat for cellular homeostasis, and the inhibition of  $H_2S$ -synthesizing enzymes may prove beneficial for cell viability (Fig. 10).

Although the mode of disulfiram's effect is not entirely clear, and it is clearly a drug with multiple modes of action, the drug (alone or in combination with copper) is currently evaluated as a candidate for drug repurposing in oncological therapy [50,27]; in fact the idea of delivering CuDDC complex in a single formulation has been recently proposed to have substantial advantages over disulfiram itself [36]. Indeed, even with the regular dosing of disulfiram (250–500 mg) used in the treatment of alcoholism, the plasma concentrations of disulfiram and its metabolites are in low (single-digit)  $\mu$ M concentration range [14,20]. These concentrations are certainly in the same concentration range where the effects of disulfiram and CuDDC were noted in the current study.

Taken together, the results presented in the current report are consistent with the conclusions that disulfiram, via its metabolite

CuDDC acts as an inhibitor of CBS and a scavenger of H<sub>2</sub>S, which, in turn, potently suppresses H<sub>2</sub>S levels in various cell types. We hypothesize that this effect may contribute to some of the previously demonstrated pharmacological actions of disulfiram and CuDDC in various oncological and non-oncological models *in vitro* and *in vivo*. Hence, (in a cell-type-specific fashion), disulfiram and/or CuDDC may be considered as potential agents for the experimental therapy of various pathophysiological conditions associated with H<sub>2</sub>S overproduction.

## 5. Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## 6. Ethics approval and consent to participate

All experiments were performed according to relevant guidelines and regulations. The current study does not involve human materials or patients.

## 7. Consent for publication

There is no contains about any individual person's data in any form and there is no need to obtain consent for publication.

## Funding

This work was supported by a grant from the LeJeune Foundation to C.S.

## CRediT authorship contribution statement

**Karim Zuhra:** Conceptualization, Methodology, Writing - original draft. **Theodora Panagaki:** Methodology. **Elisa B. Randi:** Methodology. **Fiona Augsburger:** Methodology. **Marc Blondel:** Conceptualization, Writing - review & editing. **Gaëlle Friocourt:** Writing - review & editing. **Yann Hérault:** Conceptualization, Writing - review & editing. **Csaba Szabo:** Conceptualization, Resources, Funding acquisition, Writing - review & editing.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## References

- J.L. Allensworth, M.K. Evans, F. Bertucci, A.J. Aldrich, R.A. Festa, P. Finetti, N. T. Ueno, R. Safi, D.P. McDonnell, D.J. Thiele, S. Van Laere, G.R. Devi, Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer, *Mol. Oncol.* 9 (6) (2015) 1155–1168.
- H. Antony, I.G. Macreadie, Dietary copper and the brain. In *Handbook of Behavior, Food and Nutrition*, Springer, New York, NY, 2011, pp. 2375–2392.
- F. Augsburger, C. Szabo, Potential role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H<sub>2</sub>S) pathway in cancer cells, *Pharmacol. Res.* 154 (2020), 104083.
- F. Augsburger, E.B. Randi, M. Jendly, K. Ascencio, N. Dilek, C. Szabo, Role of 3-mercaptopyruvate sulfurtransferase in the regulation of proliferation, migration, and bioenergetics in murine colon cancer cells, *Biomolecules* 10 (3) (2020) 447.
- S. Baldari, G. Di Rocco, M.C. Heffern, T.A. Su, C.J. Chang, G. Toietta, Effects of copper chelation on BRAFv600e positive colon carcinoma cells, *Cancers* 11 (5) (2019) 659.
- D. Bar-Or, L. Rael, G. Thomas, J. Kraus, Inhibitory effect of copper on cystathionine synthase activity: protective effect of an analog of the human albumin N-terminus, *Protein Pept. Lett.* 12 (2005) 271–273.
- A.K. Boal, A.C. Rosenzweig, Structural Biology of Copper Trafficking, *Chem. Rev.* 109 (10) (2009) 4760–4779.
- K. Butcher, V. Kannappan, R.S. Kilari, M.R. Morris, C. McConville, A.L. Armesilla, W. Wang, Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line, *BMC Cancer* 18 (1) (2018), <https://doi.org/10.1186/s12885-018-4617-x>.
- D. Cen, D. Brayton, B. Shahandeh, F.L. Meyskens, P.J. Farmer, Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells, *J. Med. Chem.* 47 (27) (2004) 6914–6920.
- S.M. Corsello, R.T. Nagari, R.D. Spangler, J. Rossen, M. Kocak, J.G. Bryan, R. Humeidi, D. Peck, X. Wu, A.A. Tang, V.M. Wang, S.A. Bender, E. Lemire, R. Narayan, P. Montgomery, U. Ben-David, C.W. Garvie, Y. Chen, M.G. Rees, N. J. Lyons, J.M. McFarland, B.T. Wong, L. Wang, N. Dumont, P.J. O'Hearn, E. Stefan, J.G. Doench, C.N. Harrington, H. Greulich, M. Meyerson, F. Vazquez, A. Subramanian, J.A. Roth, J.A. Bittker, J.S. Boehm, C.C. Mader, A. Tsherniak, T. R. Golub, Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling, *Nat. Cancer* 1 (2) (2020) 235–248.
- B. Cvek, Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome, *Curr. Cancer Drug Targets* 11 (3) (2011) 332–337.
- N. Druzhyna, B. Szczesny, G. Olah, K. Modis, A. Asimakopoulou, A. Pavlidou, P. Szoleczky, D. Gero, K. Yanagi, G. Toro, I. Lopez-Garcia, V. Myriantopoulos, E. Mikros, J.R. Zatarain, C. Chao, A. Papapetropoulos, M.R. Hellmich, C. Szabo, Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine beta-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer, *Pharmacol. Res.* 113 (Pt A) (2016) 18–37.
- E. Ekinici, S. Rohondia, R. Khan, Q.P. Dou, Repurposing disulfiram as an anti-cancer agent: updated review on literature and patents, *Recent Pat. Anticancer Drug Discov.* 14 (2) (2019) 113–132.
- M.D. Faïman, J.C. Jensen, R.B. Lacoursiere, Elimination kinetics of disulfiram in alcoholics after single and repeated doses, *Clin Pharmacol Ther* 36 (4) (1984) 520–526.
- M. Fatfat, R. Abou Merhi, O. Rahal, D.A. Stoyanovsky, A. Zaki, H. Haidar, V. E. Kagan, H. Gali-Muhtasib, K. Machaca, Copper chelation selectively kills colon cancer cells through redox cycling and generation of reactive oxygen species, *BMC Cancer* 14 (1) (2014) 1–12.
- A. Giuffrè, C.S. Tomé, D.G.F. Fernandes, K. Zuhra, J.B. Vicente, Hydrogen sulfide metabolism and signaling in the tumor microenvironment, *Adv. Exp. Med. Biol.* 1219 (2020) 335–353.
- A. Giuffrè, J.B. Vicente, Hydrogen Sulfide Biochemistry and Interplay with Other Gaseous Mediators in Mammalian Physiology, *Oxidative Med. Cell. Long.* 2018 (2018) 1–31.
- C.W. Huang, P.K. Moore, H<sub>2</sub>S synthesizing enzymes: biochemistry and molecular aspects, *Handb. Exp. Pharmacol.* 230 (2015) 3–25.
- A. Ichinohe, T. Kanaumi, S. Takashima, Y. Enokido, Y. Nagai, H. Kimura, Cystathionine beta-synthase is enriched in the brains of Down's patients, *Biochem. Biophys. Res. Commun.* 338 (3) (2005) 1547–1550.
- B. Johansson, A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites, *Acta Psychiatr. Scand.* 86 (S369) (1992) 15–26.
- P.P. Kamoun, Mental retardation in Down syndrome: Two ways to treat, *Med. Hypotheses* 131 (2019), 109289.
- H. Kimura, Signaling molecules: hydrogen sulfide and polysulfide, *Antioxid. Redox. Signal.* 22 (5) (2015) 362–376.
- Y. Kimura, Y. Toyofuku, S. Koike, N. Shibuya, N. Nagahara, D. Lefer, Y. Ogasawara, H. Kimura, Identification of H<sub>2</sub>S<sub>3</sub> and H<sub>2</sub>S produced by 3-mercaptopyruvate sulfurtransferase in the brain, *Sci Rep.* 5 (2015) 14774.
- F.R. Kona, D.M. Buac, A. Burger, Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies, *Curr. Cancer Drug Targets* 11 (3) (2011) 338–346.
- V. Koppaka, D.C. Thompson, Y. Chen, M. Ellermann, K.C. Nicolaou, R.O. Juvonen, D. Petersen, R.A. Deitrich, T.D. Hurley, V. Vasiliou, Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application, *Pharmacol. Rev.* 64 (3) (2012) 520–539.
- E. Lagoutte, S. Mimoun, M. Andriamihaja, C. Chaumontet, F. Blachier, F. Bouillaud, Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes, *Biochim. Biophys. Acta (BBA) - Bioenergetics* 1797 (8) (2010) 1500–1511.
- H. Li, J. Wang, C. Wu, L. Wang, Z.-S. Chen, W. Cui, The combination of disulfiram and copper for cancer treatment, *Drug Discov. Today* 25 (6) (2020) 1099–1108.
- L. Li, M. Whiteman, Y.Y. Guan, K.L. Neo, Y. Cheng, S.W. Lee, Y. Zhao, R. Baskar, C. H. Tan, P.K. Moore, Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide, *Circulation* 117 (18) (2008) 2351–2360.
- P. Liu, S. Brown, T. Goktug, P. Channathodiyil, V. Kannappan, J.-P. Hugnot, P.-O. Guichet, X. Bian, A.L. Armesilla, J.L. Darling, W. Wang, Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells, *Br. J. Cancer* 107 (9) (2012) 1488–1497.
- J. Lopez, D. Ramchandani, L. Vahdat, Copper depletion as a therapeutic strategy in cancer, *Met. Ions Life Sci.* (2019) 19.
- S.A. Lowndes, A.L. Harris, The role of copper in tumour angiogenesis, *J. Mammary Gland Biol. Neoplasia* 10 (2005) 299–310.
- N.H. Ly, T.D. Nguyen, K.D. Zoh, S.W. Joo, Interaction between diethyldithiocarbamate and Cu (II) on gold in non-cyanide wastewater, *Sensors* 17 (11) (2017) 2628.
- S. Majumder, S. Chatterjee, S. Pal, J. Biswas, T. Efferth, S.K. Choudhuri, The role of copper in drug-resistant murine and human tumors, *Biometals* 22 (2009) 377–384.
- D. Marechal, V. Brault, A. Leon, D. Martin, P. Lopes Pereira, N. Loaec, M.-C. Birling, G. Friocourt, M. Blondel, Y. Hérault, CBS overdosage is necessary and sufficient to

- induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a, *Hum. Mol. Genet.* 28 (9) (2019) 1561–1577.
- [35] Y. Matsuo, D.M. Greenberg, A crystalline enzyme that cleaves homoserine and cystathionine, *J. Biol. Chem.* 230 (1958) 545–560.
- [36] A. McMahon, W. Chen, F. Li, Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy, *J. Control Release* 319 (2020) 352–359.
- [37] K. Módis, C. Coletta, K. Erdélyi, A. Papapetropoulos, C. Szabo, Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics, *FASEB J.* 27 (2) (2013) 601–611.
- [38] W. Niu, J. Wang, J. Qian, M. Wang, P. Wu, F. Chen, S. Yan, Allosteric control of human cystathionine  $\beta$ -synthase activity by a redox active disulfide bond, *J. Biol. Chem.* 293 (7) (2018) 2523–2533.
- [39] T. Panagaki, E.B. Randi, F. Augsburger, C. Szabo, Overproduction of H<sub>2</sub>S, generated by CBS, inhibits mitochondrial Complex IV and suppresses oxidative phosphorylation in Down syndrome, *Proc. Natl. Acad. Sci. USA* 116 (38) (2019) 18769–18771.
- [40] T. Panagaki, E.B. Randi, C. Szabo, Role of 3-mercaptopyruvate sulfurtransferase in the regulation of proliferation and cellular bioenergetics in human Down syndrome fibroblasts, *Biomolecules* 10 (4) (2020) 653.
- [41] C.M. Phillips, J.R. Zatarain, M.E. Nicholls, C. Porter, S.G. Widen, K. Thanki, P. Johnson, M.U. Jawad, M.P. Moyer, J.W. Randall, J.L. Hellmich, M. Maskey, S. Qiu, T.G. Wood, N. Druzhyina, B. Szczesny, K. Módis, C. Szabo, C. Chao, M. R. Hellmich, Upregulation of cystathionine- $\beta$ -synthase in colonic epithelia reprograms metabolism and promotes carcinogenesis, *Cancer Res* 77 (21) (2017) 5741–5754.
- [42] K. Pors, J.S. Moreb, Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? *Drug Discov. Today* 19 (12) (2014) 1953–1963.
- [43] E.M. Rees, D.J. Thiele, Identification of a Vacuole-associated Metalloreductase and Its Role in Ctr2-mediated Intracellular Copper Mobilization, *J. Biol. Chem.* 282 (30) (2007) 21629–21638.
- [44] M. Rieber, Cancer pro-oxidant therapy through copper redox cycling: repurposing disulfiram and tetrathiomolybdate, *CPD* 26 (2020), <https://doi.org/10.2174/1381612826666200628022113>.
- [45] P. Rose, P.K. Moore, Y.Z. Zhu, H<sub>2</sub>S biosynthesis and catabolism: new insights from molecular studies, *Cell. Mol. Life Sci.* 74 (8) (2017) 1391–1412.
- [46] S. Singh, R. Banerjee, PLP-dependent H<sub>2</sub>S biogenesis, *Biochim. Biophys. Acta (BBA) - Proteins Proteom.* 1814 (11) (2011) 1518–1527.
- [47] S. Singh, D. Padovani, R.A. Leslie, T. Chiku, R. Banerjee, Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H<sub>2</sub>S biogenesis via alternative trans-sulfuration reactions, *J. Biol. Chem.* 284 (33) (2009) 22457–22466.
- [48] Z. Skrott, B. Cvek, Diethylthiocarbamate complex with copper: the mechanism of action in cancer cells, *Mini Rev. Med. Chem.* 12 (12) (2012) 1184–1192.
- [49] Z. Skrott, M. Mistrik, K.K. Andersen, S. Friis, D. Majera, J. Gursky, T. Ozdian, J. Bartkova, Z. Turi, P. Moudry, M. Kraus, M. Michalova, J. Vaclavkova, P. Dzubak, I. Vrobel, P. Pouckova, J. Sedlacek, A. Miklovicova, A. Kutt, J. Li, J. Mattova, C. Driessen, Q.P. Dou, J. Olsen, M. Hajduch, B. Cvek, R.J. Deshaies, J. Bartek, Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4, *Nature* 552 (7684) (2017) 194–199.
- [50] C. Szabo, Gasotransmitters in cancer: from pathophysiology to experimental therapy, *Nat. Rev. Drug Discov.* 15 (3) (2016) 185–203.
- [51] C. Szabo, A timeline of hydrogen sulfide (H<sub>2</sub>S) research: From environmental toxin to biological mediator, *Biochem. Pharmacol.* 149 (2018) 5–19.
- [52] C. Szabo, The re-emerging pathophysiological role of the cystathionine- $\beta$ -synthase-hydrogen sulfide system in Down syndrome, *FEBS J* 287 (15) (2020) 3150–3160.
- [53] C. Szabo, A. Papapetropoulos, International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H<sub>2</sub>S Levels: H<sub>2</sub>S Donors and H<sub>2</sub>S Biosynthesis Inhibitors, *Pharmacol. Rev.* 69 (4) (2017) 497–564.
- [54] C. Szabo, C. Coletta, C. Chao, K. Modis, B. Szczesny, A. Papapetropoulos, M. R. Hellmich, Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer, *Proc. Natl. Acad. Sci. USA* 110 (30) (2013) 12474–12479.
- [55] R. Wang, Physiological implications of hydrogen sulfide: a whiff exploration that blossomed, *Physiol. Rev.* 92 (2) (2012) 791–896.
- [56] P.K. Yadav, K. Yamada, T. Chiku, M. Koutmos, R. Banerjee, Structure and kinetic analysis of H<sub>2</sub>S production by human mercaptopyruvate sulfurtransferase, *J. Biol. Chem.* 288 (27) (2013) 20002–20013.
- [57] Q. Yang, Y. Yao, K. Li, L. Jiao, J. Zhu, C. Ni, M. Li, Q.P. Dou, H. Yang, An updated review of disulfiram: molecular targets and strategies for cancer treatment, *Curr. Pharm. Des.* 25 (30) (2019) 3248–3256.
- [58] K. Zuhra, F. Augsburger, T. Majtan, C. Szabo, Cystathionine- $\beta$ -synthase: molecular regulation and pharmacological inhibition, *Biomolecules* 10 (5) (2020) 697.
- [59] K. Zuhra, C.S. Tomé, L. Masi, G. Giardina, G. Paulini, F. Malagrino, E. Forte, J. B. Vicente, A. Giuffrè, N-Acetylcysteine serves as substrate of 3-mercaptopyruvate sulfurtransferase and stimulates sulfide metabolism in colon cancer cells, *Cells* 8 (8) (2019) 828.